AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Faslodex data published in Journal of Clinical Oncology.(Brief Article)
2002 OCT 3 - (NewsRx.com & NewsRx.net) -- Results from two clinical trials evaluating Faslodex (fulvestrant) Injection in treating advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy was published in the peer-reviewed Journal of Clinical Oncology.
The findings demonstrate Faslodex effectiveness and tolerability in comparison with Arimidex (anastrozole), an aromatase inhibitor, for the treatment of advanced breast cancer. The articles follow the recent approval of Faslodex by the U.S. Food and Drug Administration (FDA) for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy, such as tamoxifen. The approval was based on data from the studies (Trials 20 and 21) discussed in these articles.
"Faslodex provides a new choice for patients progressing following tamoxifen therapy," said C. Kent Osborne, MD, Baylor College of Medicine, Houston, Texas. "This published data, comparing Faslodex to an aromatase inhibitor, allows physicians to become better informed about Faslodex as a viable treatment option for postmenopausal women with advanced breast cancer."
Trial 21 was a randomized, double-blind, double-dummy, phase III study carried out in North America. The trials were designed to compare Faslodex (250 mg per month) as an intramuscular injection with Arimidex 1 mg daily oral dose. ...
- The North American Menopause Society (NAMS) Issues New Recommendations...
- Press release article from: Business Wire June 24, 2008 700+ words
...recommendations for managing breast cancer risk in postmenopausal women. Breast cancer is the most common...appropriately." While breast cancer rates have slowly declined...years, especially in postmenopausal women aged 55 to 69 years...
- Systematic Estimation of Breast Cancer Risk Appears Justified in Postmenopausal...
- Press release article from: M2 Presswire March 9, 2009 700+ words
...Screening for breast cancer risk in all postmenopausal women, using a combination...assessment of postmenopausal women for breast cancer risk with risk...Prevention of Breast Cancer in Postmenopausal Women: Approaches...
- New Clinical Trial of FASLODEX(R) (Fulvestrant) Seeks to Identify Additional...
- Press release article from: PR Newswire August 6, 2003 700+ words
...exemestane in postmenopausal women with hormone...metastatic breast cancer. The trial...metastatic breast cancer in postmenopausal women with disease...studies of postmenopausal women with breast cancer, treatment...
- Novartis Launches Z-FAST: A Study Evaluating Femara(R) and Zometa(R) in...
- Press release article from: PR Newswire December 10, 2002 700+ words
...bone loss in postmenopausal women with early breast cancer Novartis announced...treatment in postmenopausal women with early breast cancer. The Novartis...Femara, in postmenopausal women with early breast cancer in order to...
- Systematic estimation of breast cancer risk appears justified in postmenopausal...
- Magazine article from: Women's Health Weekly March 26, 2009 700+ words
...Screening for breast cancer risk in all postmenopausal women, using a...assessment of postmenopausal women for breast cancer risk with...recommended to postmenopausal women, regardless...Keywords: Breast Cancer, Breast...
- FDA Approves Femara(R) (letrozole tablets) as First-Line Hormonal Treatment For...
- Press release article from: PR Newswire January 10, 2001 700+ words
...or metastatic breast cancer. Most postmenopausal women with advanced...treatment of advanced breast cancer in postmenopausal women with disease progression...treatment for advanced breast cancer in postmenopausal women with disease ...
- FDA Advisory Committee Recommends Approval of EVISTA for the Reduction of Risk...
- Press release article from: PR Newswire July 24, 2007 700+ words
...option for postmenopausal women at increased risk for breast cancer INDIANAPOLIS...invasive breast cancer risk in two populations: postmenopausal women with osteoporosis...issues for postmenopausal women -- osteoporosis and breast cancer. ...
- FASLODEX(R) (Fulvestrant) Added to Nationally Recognized Breast Cancer...
- Press release article from: PR Newswire April 24, 2003 700+ words
...therapy for invasive breast cancer in postmenopausal women following prior...positive metastatic breast cancer in postmenopausal women with disease progression...clinical studies of postmenopausal women with breast cancer, treatment with...
- Newly Published Study Reveals Femara(R) Improves Chances for Harder to Treat...
- Press release article from: PR Newswire April 30, 2007 700+ words
...treatment option for postmenopausal women with early breast cancer that could help...early invasive breast cancer in postmenopausal women who have completed...with advanced breast cancer - Postmenopausal women with advanced...
- FDA Approves New Uses for Evista Drug Reduces Risk of Invasive Breast Cancer in...
- Press release article from: M2 Presswire September 14, 2007 700+ words
...Risk of Invasive Breast Cancer in Postmenopausal Women(C)1994-2007...risk of invasive breast cancer in postmenopausal women with osteoporosis...risk of invasive breast cancer in postmenopausal women with osteoporosis...
Source: HighBeam Research, Faslodex data published in Journal of Clinical Oncology.(Brief...